About ABEVMY

ABEVMY is a prescription medication containing the active ingredient Bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is used in the treatment of various cancers, including colorectal, lung, breast, kidney, and brain cancers.

Key Benefits & Uses

Treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy
Treatment of non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel
Treatment of recurrent glioblastoma
Treatment of metastatic breast cancer in combination with paclitaxel
Treatment of renal cell carcinoma in combination with interferon alfa

Active Ingredient & Action

Bevacizumab works by binding to VEGF, preventing its interaction with its receptors on the surface of endothelial cells, and thereby inhibiting angiogenesis, the formation of new blood vessels that tumors need to grow and spread.

Important Notes

ABEVMY should be used under the guidance of a qualified healthcare professional. Common side effects include hypertension, proteinuria, and thromboembolic events. Patients with a history of hemoptysis or gastrointestinal fistulae should not receive ABEVMY. It is essential to monitor blood pressure and renal function regularly during treatment.